S-1: IR-Med Files for Nasdaq IPO, Offering Units of Common Stock and Warrants

IR-Med, a medical device company focused on non-invasive diagnostic solutions, has filed an S-1 registration statement for a proposed IPO to list its common stock and warrants on the Nasdaq Capital Market.

Summary

• IR-Med, Inc., a Nevada corporation, has filed a Form S-1 registration statement with the SEC for a proposed initial public offering.
• The offering involves units, each consisting of one share of common stock and one warrant to purchase one share of common stock.
• The company intends to list its common stock and warrants on the Nasdaq Capital Market under the symbols IRME and IRMEW, respectively.
• The company is developing point-of-care decision support devices based on infrared spectroscopy and artificial intelligence, with a focus on early detection of pressure injuries and diabetic foot ulcers.
• The lead product, PressureSafe, has received FDA listing certification as a Class I device and is planned for commercial launch in September 2024.
• The company recently closed a private placement offering, raising $715,000 through the sale of common stock and warrants.
• The company is a smaller reporting company and has elected to take advantage of certain scaled disclosure requirements.
• The company acknowledges that investing in its common stock involves a high degree of risk.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential of the company's technology and the risks associated with investing in a development-stage medical device company. The company has achieved some milestones, such as FDA listing certification for PressureSafe, but faces significant challenges in securing funding and achieving profitability.

Positives

• PressureSafe has received FDA listing certification, paving the way for commercial launch.
• The company is developing innovative diagnostic solutions using AI and infrared spectroscopy.
• The company is targeting large and growing markets with unmet medical needs.
• The company has secured a grant from the Israeli Innovation Authority for the development of DiaSafe.
• The company intends to use a disposable unit/pay per use business model.

Negatives

• The company has a history of significant operating losses and expects to continue incurring losses.
• The company will need substantial additional funding to continue its operations.
• There is no assurance that the company's application to list on Nasdaq will be approved.
• There is not now, and there may never be, an active, liquid and orderly trading market for the company's common stock.
• The company is exposed to additional risks as a result of going public by means of a reverse acquisition transaction.

Risks

• The company may not be able to raise capital when needed, which could force it to delay or eliminate product development programs.
• Medical device development is a lengthy and expensive process with an uncertain outcome.
• The company currently has no products that are approved for commercial sale.
• The size and future growth in the market for the company's planned devices has not been established with precision.
• The company may be subject to numerous and varying privacy and security laws.
• The company's technology development is headquartered in Israel, and its results may be adversely affected by political and military instability.
• The company may have become exposed to material liabilities that were not discovered before, and have not been discovered since, due to the closing of the Acquisition.
• If the company fails to maintain proper and effective internal controls, its ability to produce accurate and timely financial statements could be impaired.

Future Outlook

The company plans to use the net proceeds from this offering for the development efforts of its products, while mainly focusing on the DiaSafe device, production of commercial units, marketing, and working capital.

Industry Context

The company operates in the medical device industry, specifically targeting the diagnostics market with a focus on point-of-care solutions. The company's products aim to address unmet needs in early detection of pressure injuries and diabetic foot ulcers, which are significant healthcare burdens.

Comparison to Industry Standards

• The document mentions Bruins Biometrics Provizio SEM Scanner as a competitor in the pressure injury detection market.
• IR-Med's PressureSafe device uses infrared spectroscopy and AI, while the Bruin scanner uses electro-resistance measurement of skin moisture.
• The document does not provide a detailed comparison of the performance or cost-effectiveness of the two devices.

Management Changes

Legal Proceedings

• The company is involved in a lawsuit filed in the Tel Aviv District Court of Israel, alleging breach of contract and seeking damages of approximately $2.1 million. The company believes the allegations are baseless and intends to vigorously defend its rights.

Related Party Transactions

• In 2015, the subsidiary received loans from certain of its former stockholders.
• In 2017, the subsidiary received a loan from one of its former stockholders.
• In March 2018, certain of the subsidiary's shareholders advanced to it a convertible bridge loan.
• For the years ended December 31, 2023, and 2022, the company paid to two directors and to an entity controlled by a shareholder of the company an aggregate consideration of US$161 thousand and US$220 thousand, respectively, in respect of research and development services.
• For the years ended December 31, 2023, and 2022, the company paid to one shareholder of the company and his relative an aggregate consideration of $150 thousand and $111 thousand, respectively in respect consulting services.
• For the years ended December 31, 2023, and 2022, the company paid to four of the company non-employee directors an aggregate consideration of $36 thousand and $130 thousand respectively in respect of their services.
• For the year ended December 31, 2023, the company paid to four of its officers, salary and related expenses that totaled to $439 thousand.
• For the year ended December 31, 2022, the company paid to one director of the company and four of its officers, salary and related expenses totaled to $651 thousand, respectively, in respect thereof.
• For the years ended December 31, 2023, and 2022, the company paid a yearly amount of $80 thousand and $51 thousand to an entity controlled by two of the company's directors for rent and office services, respectively.
• Following the adoption of the 2020 incentive stock plan (hereinafter the Plan) by the company on December 23, 2020, and the adoption of the sub plan (the Israeli appendix) on April 29, 2021, the company granted during the years 2023 and 2022 to its directors, officers, and shareholder 1,636,000 and 5,200,000 options to purchase shares of Common Stock respectively.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's success depends on market acceptance of its products by healthcare providers and patients.
• The company's ability to attract and retain key personnel is crucial for its success.
• The company's operations are subject to risks related to political and military instability in Israel.

Next Steps

• Complete the development of the commercial version of the PressureSafe device.
• Launch PressureSafe commercially in September 2024.
• Continue development of DiaSafe and initiate clinical studies.
• Seek additional funding to support operations and product development.

Key Dates

Keywords

IPO, initial public offering, IR-Med, PressureSafe, DiaSafe, medical devices, warrants, Nasdaq, infrared spectroscopy, artificial intelligence, diagnostic devices, FDA, OTCQB